about
Diversity and functional consequences of germline and somatic PTPN11 mutations in human disease.Computer aided analysis of additional chromosome aberrations in Philadelphia chromosome positive acute lymphoblastic leukaemia using a simplified computer readable cytogenetic notationNucleophosmin gene mutations are predictors of favorable prognosis in acute myelogenous leukemia with a normal karyotype.Implications of NRAS mutations in AML: a study of 2502 patients.Morphologic dysplasia in de novo acute myeloid leukemia (AML) is related to unfavorable cytogenetics but has no independent prognostic relevance under the conditions of intensive induction therapy: results of a multiparameter analysis from the GermaThe t(8;9)(p22;p24) is a recurrent abnormality in chronic and acute leukemia that fuses PCM1 to JAK2Isochromosome breakpoints on 17p in medulloblastoma are flanked by different classes of DNA sequence repeatsEarly blast clearance by remission induction therapy is a major independent prognostic factor for both achievement of complete remission and long-term outcome in acute myeloid leukemia: data from the German AML Cooperative Group (AMLCG) 1992 Trial.Diagnostic tool for the identification of MLL rearrangements including unknown partner genesAcute myeloid leukemias with reciprocal rearrangements can be distinguished by specific gene expression profilesClinical trial of valproic acid and all-trans retinoic acid in patients with poor-risk acute myeloid leukemia.Analysis of FLT3 length mutations in 1003 patients with acute myeloid leukemia: correlation to cytogenetics, FAB subtype, and prognosis in the AMLCG study and usefulness as a marker for the detection of minimal residual disease.Acute myeloid leukemia: treatment over 60.Cytogenetics in acute myeloid leukemia.Gene expression profiling as a tool for the diagnosis of acute leukemias.FLT3 length mutations as marker for follow-up studies in acute myeloid leukaemia.Gene expression profiling as a diagnostic tool in acute myeloid leukemia.Acute myeloid leukemia with a complex aberrant karyotype is a distinct biological entity characterized by genomic imbalances and a specific gene expression profile.Role of gene expression profiling for diagnosing acute leukemias.Monitoring of minimal residual disease in acute myeloid leukemia.Modern diagnostics in acute leukemias.Treatment of older patients with AML.Treatment of AML in biological subgroups.Distinct sequences on 11q13.5 and 11q23-24 are frequently coamplified with MLL in complexly organized 11q amplicons in AML/MDS patients.Gain of 9p due to an unbalanced rearrangement der(9;18): a recurrent clonal abnormality in chronic myeloproliferative disorders.Loss of genetic material is more common than gain in acute myeloid leukemia with complex aberrant karyotype: a detailed analysis of 125 cases using conventional chromosome analysis and fluorescence in situ hybridization including 24-color FISH.Effect of histone deacetylase inhibitor valproic acid on progenitor cells of acute myeloid leukemia.Comparison of mRNA abundance quantified by gene expression profiling and percentage of positive cells using immunophenotyping for diagnostic antigens in acute and chronic leukemias.KIT-D816 mutations in AML1-ETO-positive AML are associated with impaired event-free and overall survival.A new prognostic score for patients with acute myeloid leukemia based on cytogenetics and early blast clearance in trials of the German AML Cooperative Group.Correlation of protein expression and gene expression in acute leukemia.Molecular characterization of acute leukemias by use of microarray technology.Expression analyses identify MLL as a prominent target of 11q23 amplification and support an etiologic role for MLL gain of function in myeloid malignancies.CS-1, a novel c-kithi+ acute myeloid leukemia cell line with dendritic cell differentiation capacity and absent immunogenicity.CD40L stimulation enhances the ability of conventional metaphase cytogenetics to detect chromosome aberrations in B-cell chronic lymphocytic leukaemia cells.Early prediction of response in patients with relapsed or refractory Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ALL) treated with imatinib.Increased risk for therapy-associated hematologic malignancies in patients with carcinoma of the breast and combined homozygous gene deletions of glutathione transferases M1 and T1.The influence of age on prognosis of de novo acute myeloid leukemia differs according to cytogenetic subgroups.A new and recurrent activating length mutation in exon 20 of the FLT3 gene in acute myeloid leukemia.Rapid diagnostic approach to PML-RARalpha-positive acute promyelocytic leukemia.
P50
Q24540529-E15E834A-A5C2-41E0-B40E-535C624352C3Q24798120-0B12A68D-D460-4660-B1FB-524978873109Q27824844-72F45CCC-CCED-4263-963F-858D0141EB26Q27824859-D8E9C61D-6B20-4E1C-BB6E-F3459503D474Q28202843-E8A08940-81C8-4B5B-8765-0D081E0032E0Q28243103-86ECDADD-FC3E-4A45-889C-E572439F8E9AQ29037387-6CCE4283-B302-4F8D-BD67-6758AB1777F2Q30741760-EF00ABFE-7FCB-4E57-A452-1D8C578EAA2AQ33723050-AEE00129-0882-494C-B93C-764155258502Q34098676-00826C22-E0FF-4753-BF59-7C17D9273828Q34468570-D758F819-1255-4198-8EAE-14614936DE51Q34524219-A69C4A64-A868-49A7-9757-BC3FC7941F83Q34680938-C5446C84-D985-4DC4-80E6-FF9FDE2CB6C9Q34774170-ACD8776A-ECAC-464D-BEB5-1627B6269510Q35569561-5A3B1892-CA11-42B6-9565-E9D9F0E83A44Q35792858-FF9CEC25-C413-4311-A713-0E81402AB6A9Q35852754-CC596ECF-BCFF-4903-895F-B3240C36C25AQ36104615-96AE36B6-E238-431A-9679-6591E8A5E115Q36199389-62EA6F04-AA00-45DD-BBBD-661D7422715EQ36280657-6E3840B1-6DD2-41B6-B918-027DCB7CD633Q36280666-7425DEC3-8676-49D8-8ED5-082544AB99A2Q36295817-19F8F6DB-59B6-4458-8F34-7916534C2BA4Q36308975-CF647C47-611D-4884-9357-F606FE1673A4Q38344493-B8B3C485-8CB6-48D1-A78A-3AD48E09140DQ38473283-C280DEBB-0CC5-4CF3-88CC-C5707F0D0D83Q38487721-D6AE346B-F941-4F85-A33B-C6E7DC1C0EA3Q40135154-9919DF3F-C922-48F0-A72E-892B4CDEC41FQ40279015-ACC5EDDD-4C47-4AC3-856F-DB6547C26A01Q40357255-03CA3E5C-2B66-4573-BDAE-81B02255CC0FQ40518392-5EB59176-FEF6-4087-A46B-C88F3498F991Q40564976-C14FE901-9760-46ED-BC70-483F4D56A74FQ40582234-92A248FA-FF7D-4EEC-9CC6-0605E557E968Q40639306-F90ADB6D-A7F7-420D-A51A-4593D31E5082Q40658697-8E56C582-56A5-49F0-992C-637953FB834DQ42811066-BC6B6878-9E71-4367-B706-F3088CA97C88Q43473669-572E11F8-5B82-4327-86AF-35610C320570Q43855423-4C690AEC-3BCB-4214-94E4-F1674E2D1660Q43896810-0767AAFF-01FA-46C0-BFDC-F9CAF047CDBFQ44182964-DEF6F01C-956D-4E73-85A2-009B92CD344CQ44187920-8BA62478-D256-45F6-9385-3D7DAC470690
P50
description
researcher
@en
name
Claudia Schoch
@ast
Claudia Schoch
@en
Claudia Schoch
@nl
type
label
Claudia Schoch
@ast
Claudia Schoch
@en
Claudia Schoch
@nl
prefLabel
Claudia Schoch
@ast
Claudia Schoch
@en
Claudia Schoch
@nl